TMEM16A overexpression contributes to tumor invasion and poor prognosis of human gastric cancer through TGF-β signaling
- PMID: 25839162
- PMCID: PMC4484478
- DOI: 10.18632/oncotarget.3412
TMEM16A overexpression contributes to tumor invasion and poor prognosis of human gastric cancer through TGF-β signaling
Abstract
TMEM16A is a newly identified calcium activated chloride channel, and has been reported to be overexpressed by various solid malignant cancers to promote proliferation and invasion, yet little is known about its role in gastric cancer(GC). Therefore, we investigated the role of TMEM16A in GC and its clinical significance by a retrospective analysis of 367 GC patients, and in vitro study was performed for validation and underlying molecular mechanism.TMEM16A was significantly upregulated and amplified in GC tissues, and its overexpression was positively correlated with disease stage, negatively with patient survival and identified as an independent prognostic factor for patient outcome. A negative correlation between TMEM16A and E-cadherin was found in 367 GC specimens. TMEM16A silencing significantly decreased calcium activated chloride currents, impaired TGF-β secretion, reduced E-cadherin expression, and inhibited the migration and invasion without affecting proliferation of GC cells (AGS and BGC-823). Supplement of TGF-β reverted the effects of TMEM16A silencing on E-cadherin expression, cell migration and invasion.In conclusion, TMEM16A promotes invasion and metastasis in GC, and might be a novel prognostic biomarker and potential therapeutic target in the treatment of GC.
Keywords: TGF-β; TMEM16A; gastric cancer; invasion; prognosis.
Conflict of interest statement
The authors declared no potential conflicts of interest.
Figures








Similar articles
-
Overexpression of HOXA10 promotes gastric cancer cells proliferation and HOXA10(+)/CD44(+) is potential prognostic biomarker for gastric cancer.Eur J Cell Biol. 2015 Dec;94(12):642-52. doi: 10.1016/j.ejcb.2015.08.004. Epub 2015 Nov 6. Eur J Cell Biol. 2015. PMID: 26552644
-
A Long Non-coding RNA Activated by Transforming Growth Factor-β is an Independent Prognostic Marker of Gastric Cancer.Ann Surg Oncol. 2015 Dec;22 Suppl 3:S915-22. doi: 10.1245/s10434-015-4554-8. Epub 2015 May 19. Ann Surg Oncol. 2015. PMID: 25986864
-
Mitogen-activated protein kinase activator with WD40 repeats (MAWD) and MAWD-binding protein induce cell differentiation in gastric cancer.BMC Cancer. 2015 Sep 15;15:637. doi: 10.1186/s12885-015-1637-7. BMC Cancer. 2015. PMID: 26373288 Free PMC article.
-
Dysregulation of miRNAs as a signature for diagnosis and prognosis of gastric cancer and their involvement in the mechanism underlying gastric carcinogenesis and progression.IUBMB Life. 2020 May;72(5):884-898. doi: 10.1002/iub.2259. Epub 2020 Feb 20. IUBMB Life. 2020. PMID: 32078236 Review.
-
Correlation of cadherin-17 protein expression with clinicopathological features and prognosis of patients with sporadic gastric cancer.Braz J Med Biol Res. 2015 Dec;48(12):1077-86. doi: 10.1590/1414-431X20154645. Epub 2015 Sep 29. Braz J Med Biol Res. 2015. PMID: 26421870 Free PMC article. Review.
Cited by
-
Function and Regulation of the Calcium-Activated Chloride Channel Anoctamin 1 (TMEM16A).Handb Exp Pharmacol. 2024;283:101-151. doi: 10.1007/164_2022_592. Handb Exp Pharmacol. 2024. PMID: 35768554
-
Expression of ANO1/DOG1 is associated with shorter survival and progression of breast carcinomas.Oncotarget. 2017 Dec 9;9(1):607-621. doi: 10.18632/oncotarget.23078. eCollection 2018 Jan 2. Oncotarget. 2017. PMID: 29416639 Free PMC article.
-
Ion channels or aquaporins as novel molecular targets in gastric cancer.Mol Cancer. 2017 Mar 6;16(1):54. doi: 10.1186/s12943-017-0622-y. Mol Cancer. 2017. PMID: 28264681 Free PMC article. Review.
-
Deficiency of TTYH1 Expression Reduces the Migration and Invasion of U2OS Human Osteosarcoma Cells.Life (Basel). 2022 Apr 3;12(4):530. doi: 10.3390/life12040530. Life (Basel). 2022. PMID: 35455021 Free PMC article.
-
Gastric Cancer: Identification of microRNAs Inhibiting Druggable Targets and Mediating Efficacy in Preclinical In Vivo Models.Cancer Genomics Proteomics. 2021 Jul-Aug;18(4):497-514. doi: 10.21873/cgp.20275. Cancer Genomics Proteomics. 2021. PMID: 34183383 Free PMC article. Review.
References
-
- Ajani JA, Bentrem DJ, Besh S, D'Amico TA, Das P, Denlinger C, Fakih MG, Fuchs CS, Gerdes H, Glasgow RE, Hayman JA, Hofstetter WL, Ilson DH, Keswani RN, Kleinberg LR, Korn WM, Lockhart AC, Meredith K, Mulcahy MF, Orringer MB, Posey JA, Sasson AR, Scott WJ, Strong VE, Varghese TK, Jr, Warren G, Washington MK, Willett C, Wright CD, McMillian NR, Sundar H, National Comprehensive Cancer N. Gastric cancer, version 2.2013: featured updates to the NCCN Guidelines. J Natl Compr Canc Netw. 2013;11:531–546. - PubMed
-
- NCCN Clinical Practice Guidelines in Oncology. Gastric cancer. 2014;55:2014. V.1.2014. Available at_ http://www.nccn.org/professionals/physician_gls/f_guidelines.asp.
-
- Macdonald JS. Gastric cancer—new therapeutic options. N Engl J Med. 2006;355:76–77. - PubMed
-
- Yilmaz M, Christofori G. Mechanisms of motility in metastasizing cells. Mol Cancer Res. 2010;8:629–642. - PubMed
-
- Caputo A, Caci E, Ferrera L, Pedemonte N, Barsanti C, Sondo E, Pfeffer U, Ravazzolo R, Zegarra-Moran O, Galietta LJ. TMEM16A, a membrane protein associated with calcium-dependent chloride channel activity. Science. 2008;322:590–594. - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Miscellaneous